This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2013 by Bandim Health Project.
Recruitment status was:  Active, not recruiting
Information provided by:
Bandim Health Project Identifier:
First received: July 3, 2008
Last updated: November 14, 2013
Last verified: November 2013
Our group has discovered that routine vaccinations in childhood may have non-specific and sex-differential effects on overall mortality. The effects are so large that they may have marked effects on overall mortality and seriously distort female-to-male mortality rates in high-mortality settings. We recently experienced periods during which oral polio vaccine (OPV) was lacking. Hence, some children did not get the recommended OPV at birth. We were following all infants as a part of a vitamin A supplementation trial. Surprisingly, we discovered that not receiving OPV was associated with significantly lower mortality in boys, but not in girls. We bled a subgroup of the children. Receiving OPV at birth significantly dampened the immunological response to BCG given at birth in both sexes. Based on these observations, receiving OPV at birth may have two negative effects, first, it may increase male mortality, and second, it may interfere with immunity against tuberculosis. OPV at birth is given for logistic reasons, to boost polio immunity. There have been no polio cases in Guinea-Bissau for the last 10 years. Hence, there is every reason to test in a randomised trial whether not receiving OPV at birth is associated with 1) mortality, morbidity and growth and 2) immunological response to BCG.

Condition Intervention
Infant, Newborn Healthy Biological: Oral polio vaccine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth

Resource links provided by NLM:

Further study details as provided by Bandim Health Project:

Primary Outcome Measures:
  • Mortality by sex

Secondary Outcome Measures:
  • Morbidity, growth, immunology

Study Start Date: July 2008
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Oral polio vaccine
Biological: Oral polio vaccine
No Intervention: B
No oral polio vaccine


Ages Eligible for Study:   up to 1 Month   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:Normal birth weight, no overt illness or gross malformations -

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00710983

Bandim Health Project
Bissau, Guinea-Bissau
Sponsors and Collaborators
Bandim Health Project
Principal Investigator: Peter Aaby, DMSc Bandim Health Project
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Peter Aaby, Bandim Health Project Identifier: NCT00710983     History of Changes
Other Study ID Numbers: 2008-7041-122
Study First Received: July 3, 2008
Last Updated: November 14, 2013

Keywords provided by Bandim Health Project:

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on September 20, 2017